Jessica Baker Flechtner - 15 Mar 2022 Form 4 Insider Report for GENOCEA BIOSCIENCES, INC.

Role: Chief Scientific Officer
Signature: /s/ Diantha Duvall, Attorney-in-Fact for Jessica Flechtner
Issuer symbol: N/A
Transactions as of: 15 Mar 2022
Net transactions value: -$3,684
Form type: 4
Filing time: 17 Mar 2022, 16:12:39 UTC
Previous filing: 16 Mar 2022
Next filing: 05 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GNCA	Common Stock	Award	$0	+43,750	+77%	$0.000000	100,754	15 Mar 2022	Direct	F1
transaction	GNCA	Common Stock	Sale	$3,684	-3,349	-3.3%	$1.10	97,405	16 Mar 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GNCA	Stock Option (Right to Buy)	Award	$0	+131,250		$0.000000	131,250	15 Mar 2022	Common Stock	131,250	$1.11	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date.
F2	Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
F3	The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.